Equities analysts expect Endo International PLC (NASDAQ:ENDP) (TSE:ENL) to report $0.53 earnings per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Endo International’s earnings, with the highest EPS estimate coming in at $0.57 and the lowest estimate coming in at $0.49. Endo International posted earnings per share of $0.71 during the same quarter last year, which would indicate a negative year-over-year growth rate of 25.4%. The business is expected to announce its next earnings results on Thursday, November 14th.
According to Zacks, analysts expect that Endo International will report full year earnings of $2.17 per share for the current fiscal year, with EPS estimates ranging from $2.11 to $2.23. For the next financial year, analysts forecast that the business will post earnings of $2.34 per share, with EPS estimates ranging from $1.71 to $3.13. Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that cover Endo International.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Monday, August 5th. The company reported $0.52 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.05. The company had revenue of $699.71 million during the quarter, compared to the consensus estimate of $694.60 million. Endo International had a negative net margin of 19.98% and a negative return on equity of 129.30%. The company’s revenue for the quarter was down 2.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.76 earnings per share.
Shares of NASDAQ ENDP traded up $0.23 during mid-day trading on Friday, hitting $4.23. The company’s stock had a trading volume of 4,672,495 shares, compared to its average volume of 8,880,766. Endo International has a one year low of $1.97 and a one year high of $18.50. The stock has a market cap of $922.72 million, a price-to-earnings ratio of 1.46 and a beta of 1.23. The company’s fifty day simple moving average is $2.76 and its 200-day simple moving average is $5.67.
In related news, Director Roger H. Kimmel sold 34,951 shares of the stock in a transaction dated Monday, June 17th. The stock was sold at an average price of $3.93, for a total transaction of $137,357.43. Following the completion of the sale, the director now owns 148,309 shares in the company, valued at $582,854.37. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.50% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Oregon Public Employees Retirement Fund increased its position in shares of Endo International by 1.8% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 77,330 shares of the company’s stock valued at $621,000 after purchasing an additional 1,397 shares during the last quarter. Mason Street Advisors LLC lifted its stake in shares of Endo International by 3.4% during the first quarter. Mason Street Advisors LLC now owns 64,141 shares of the company’s stock worth $515,000 after buying an additional 2,134 shares during the period. Piedmont Investment Advisors Inc. grew its stake in shares of Endo International by 5.8% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock worth $407,000 after purchasing an additional 2,795 shares during the period. Comerica Bank increased its stake in shares of Endo International by 2.1% in the 1st quarter. Comerica Bank now owns 198,605 shares of the company’s stock valued at $1,650,000 after purchasing an additional 4,001 shares in the last quarter. Finally, Arizona State Retirement System raised its position in Endo International by 1.4% during the second quarter. Arizona State Retirement System now owns 312,262 shares of the company’s stock worth $1,287,000 after acquiring an additional 4,167 shares during the period. 95.80% of the stock is currently owned by institutional investors.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Further Reading: Buyback
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.